The precision-engineering screen: 3 qualifiers, 3 near-misses, and the balance-sheet line that separated them

If you have been reading precision-engineering results this season, you have already seen the trap. The fastest profit growth in the sector came from companies whose balance sheets moved the wrong way. PTC Industries grew profit 466% and still added leverage. Ramkrishna Forgings saw reported ROCE collapse from 40.9% to 6.4% even as its operating margins improved. The income statement told one story; the balance sheet told another.

This article applies a strict, pre-set screen to 52 listed precision-engineering companies and separates the three that cleared every gate from the three that failed the one gate that matters most: whether leverage is falling and returns on capital are rising. It is a descriptive exercise, not a stock recommendation.

The screen had seven gates: Q1 FY27 revenue growth of at least 10%, EBITDA margin expansion, EPS growth, a price within 5% of the 52-week high, a one-month return of at least 10%, and the balance-sheet pair of falling debt/equity and rising ROCE. Any company that failed a single criterion was out, no matter how good the quarter.

Seven gates, and the one that did the separating

The funnel narrows quickly. Of the 52 listed companies in the precision-engineering universe, 35 had comparable Q1 FY27 and Q1 FY26 statements. Twelve passed the income tests. Six passed the price tests. Three cleared the balance-sheet gate. The other 16 names had no extracted Q1 data and could not be screened at all.

The separator deserves emphasis. Three companies passed revenue, margin, EPS and price tests and still missed the final list, because debt/equity rose or ROCE fell on the point-in-time ratio panel between July 2025 and July 2026. Growth tests measure a quarter; the balance-sheet tests measure a trajectory.

What Q1 FY27 actually said

Across the six finalists, reported revenue growth ranged from +13.8% (Shaily) to +83.0% (PTC Industries), and PAT growth from +16.8% to +466.2%. Every company expanded its headline margin year on year, though the headline metric differs by company (PBT margin for Kennametal, net margin for Investment & Precision Castings, EBITDA margin for the rest).

The important observation is not that margins expanded everywhere. It is that the two widest expansions belong to companies that were later excluded, and the companies that cleared the balance-sheet gate expanded margins by less. Headline growth alone did not separate the winners from the near-misses.

The three qualifiers: growth that survived the balance sheet

Kennametal India: operating leverage, not price pass-through

Q1 performance. Kennametal India's fiscal year ends in June, so its latest reported quarter (April to June 2026) is the comparable period here. Revenue rose 47.7% to ₹477.6 Cr while total expenses grew only 26.2%. PBT nearly tripled to ₹118.4 Cr, net profit rose 183.7% to ₹88.8 Cr and EPS was ₹40.39 versus ₹14.22. The PBT margin went from 12.8% to 24.8%, a 1,200 bps expansion. The quarter was almost entirely a Hard Metal story: that segment contributed 93.7% of revenue, grew 60.7% and swung segment profit up 207.8%, with its segment margin doubling from 16.2% to 31.0%. Machining Solutions fell 32.7% and turned to a ₹9.2 Cr segment loss.

Quality and sustainability. The expansion was driven by volume and mix, not one-off pricing: management cited "broad-based demand across end-use segments" and operational excellence while navigating "headwinds from an unprecedented tungsten environment." For full-year FY26, revenue rose 29.1% to ₹1,510.7 Cr and net profit rose 90.5% to ₹196.0 Cr. Two caveats temper the picture: part of Hard Metal's revenue surge may be tungsten price pass-through that normalises, and Machining Solutions remains loss-making. No specific FY27 guidance was disclosed in the retrieved documents.

Deleveraging and ROCE. The balance sheet is effectively a non-issue in the best sense: zero debt throughout the panel, net debt/EBITDA of minus 0.15, and interest coverage so high it is not a constraint. ROCE rose from 20.1% to 23.6% over the available panel trajectory (the year-ago point is not available; the earliest reading is November 2025) and stands at 31.2% on live TTM data, with ROE at 23.0%. Capex is only 3.5% of revenue, so growth is not consuming cash.

Three growth drivers.
1. Hard Metal cutting tools and wear solutions, exposed to automotive, general engineering, mining and construction, aerospace and MSME end-markets, which together drive roughly 90% of revenue.
2. Aerospace and defence plus the infrastructure capex cycle, including the ₹11.2 trillion capital expenditure allocation in the FY26 Union Budget.
3. Capacity and import substitution: the new inserts manufacturing facility in Bengaluru, identified Hard Metal capacity increases, in-house powder manufacturing and indigenisation of refractory-carbide production.

Shaily Engineering Plastics: healthcare crossed half the mix

Q1 performance. Revenue rose 13.8% to ₹281 Cr, with the Healthcare segment growing 84.4% to ₹142 Cr and crossing 50% of total revenue for the first time. The Consumer segment fell 23.2% to ₹116 Cr, and Industrial grew 27.8% to ₹23 Cr. EBITDA was ₹83 Cr at a 29.7% margin, up 120 bps, helped by the higher-margin healthcare mix and improved machine utilisation (50.2% versus 48.7%). PAT rose 16.8% to ₹48 Cr on the structured filing basis (the company's announcement reported +17.1%, a rounding difference), with EPS at ₹10.45 versus ₹8.95.

Quality and sustainability. The mix shift is structural. Pen injectors for GLP-1 and insulin therapies carry higher margins than home furnishings, and Shaily delivered about 9 million devices in Q1, 50% to 60% of it linked to Semaglutide. Two new platform projects were signed in the quarter, partnership talks with a major global pharmaceutical company are underway, and management is confident of exceeding the FY27 pen guidance of 36 million units, with pen capacity rising from about 50 million to about 75 million units per annum by end-September 2026. The risks are on the other side: Consumer is in its third consecutive quarter of decline, and FY26 pen volumes of 23.3 to 23.5 million missed the guided 25 to 26 million on capacity constraints.

Deleveraging and ROCE. Debt/equity fell from 0.343 to 0.243 and ROCE rose from 23.0% to 26.8% on the panel; live ROE is 24.7% and live ROCE 27.9%. Net debt/EBITDA is 0.51x, interest coverage 16.2x, and operating cash flow is 75% of EBITDA, with a positive FCF margin of 4.6%.

Three growth drivers.
1. Drug-delivery devices, above all pen injectors for GLP-1 and insulin, the single largest hook in the portfolio.
2. New healthcare platforms and partnerships: two platform projects signed in Q1, a semiconductor-tray partnership with a Korean partner, and the new Abu Dhabi facility.
3. Consumer-electronics diversification: five components awarded, with roughly US$10 million of revenue potential over 24 to 30 months.

Investment & Precision Castings: small scale, clean operating leverage

Q1 performance. Revenue rose 21.2% to ₹53.34 Cr while total expenses grew only 12.4%, and net profit more than doubled, up 129.5% to ₹4.99 Cr. The net margin expanded from 4.94% to 9.36%, a 442 bps move, with EPS at ₹4.99 versus ₹2.17 and zero exceptional items. Results were announced on 13 August 2026.

Quality and sustainability. The profit jump is arithmetic, and it is entirely operational: revenue outpaced expenses by about nine percentage points, and the effective tax rate was not a tailwind. The trajectory predates the quarter: PBILDT margin improved from 13.92% in FY25 to 16.80% in FY26, interest coverage rose from 3.36x to 5.04x, and CARE Ratings assigned a Stable outlook citing "growth in scale, improved profitability, and better debt coverage." On the strategic side, the company has booked defence orders from GTRE DRDO (HP-turbine superalloy castings, February 2026), MKU Limited (thermal weapon-sight components, April 2026) and PLR Systems (July 2025), and holds series-production approval from an international aerospace customer for civil-aviation aluminium investment castings. Order values are not disclosed, and automotive remains the majority of sales (59% in FY25), so this is an early-stage diversification.

Deleveraging and ROCE. Debt/equity fell from 0.707 to 0.683 and ROCE rose from 9.5% to 13.4% on the panel; live ROE is 14.2% and live ROCE 15.8%. Net debt/EBITDA is 1.88x and interest coverage 4.3x, the tightest of the three qualifiers, but capex is only 12.2% of revenue because the company operates at roughly 50% of installed capacity (about 1,500 tons produced against 3,060 tons across three plants).

Three growth drivers.
1. Defence and aerospace orders: GTRE DRDO, MKU and PLR Systems, with Plant 3 dedicated exclusively to aerospace and defence.
2. Capacity headroom: about 50% of installed capacity is idle, so volume can grow without major capex.
3. Margin expansion: a captive 4 MW solar plant, process optimisation, and an ex-works export model that keeps US tariffs off the company's margins.

The near-misses: spectacular quarters, wrong-direction balance sheets

The next two charts are the whole argument in visual form. The qualifiers improved both ROCE and debt/equity. The near-misses show at least one line moving the wrong way, and in RKFORGE's case both.

PTC Industries: the fastest growth in the screen, funded the wrong way

Q1 performance. Total income rose 83.0% to ₹197.1 Cr (revenue from operations grew even faster, 97.4%, on a slightly different definition). EBITDA was ₹54.2 Cr at a 27.5% margin, up 954 bps, and PAT was ₹29.2 Cr, up 466.2%, at a 14.8% margin. The engine is Aerolloy Technologies, the titanium and superalloy casting subsidiary: ₹74.3 Cr of income, up 466.4%, at a 45.0% EBITDA margin, contributing ₹22.1 Cr of PAT, roughly 76% of the consolidated total. The UK subsidiary TRAC Precision generated ₹71.4 Cr of revenue at only about an 8.5% EBITDA margin.

Quality and sustainability. The ramp is programme-diversified: an Airbus framework agreement covering titanium castings for the A320neo, A330neo and A350; a BrahMos missile sub-system order; design and development work for ARDE-DRDO and Gun Factory Kanpur; and a deepening Blue Origin BE-4 partnership for flight-critical space hardware. The platform is integrated, with VIM/VAR/PAM melting through casting, forging and machining under one roof, and the 4500/5100T open-die forging system commissioned. ICRA upgraded the rating to A (Stable) from A-. Two caveats: Q1's 27.5% EBITDA margin is an 810 bps sequential contraction from the record Q4 FY26 level of 35.6%, and the FY26 full-year margin of 26.8% was well below that Q4 exit rate, suggesting the year-end spike was not the steady state. No order-book or customer-concentration figures were disclosed in the retrieved materials, and no one-off items were found, though the notes to accounts would be the place to confirm that.

Why it failed the screen. Debt/equity rose from 0.044 to 0.173. Live TTM data shows net debt/EBITDA of 1.09x and interest coverage of 15.6x, which are comfortable, but CFO/EBITDA of minus 33.1%, capex at 45.5% of revenue and an FCF margin of minus 55.3% tell the real story: growth is outspending operating cash flow and being funded with debt. ROCE did improve, from 6.0% to 7.7%, but from a low base, and the leverage leg runs exactly opposite to what the screen requires.

Three growth drivers.
1. The commercial aerospace titanium ramp: the Airbus framework covers development, qualification, industrialisation and future supply of fully machined titanium castings.
2. Defence and systems integration: the BrahMos order moves the company from components into sub-systems, alongside the ARDE-DRDO and Gun Factory Kanpur work.
3. Space propulsion: the deepening Blue Origin BE-4 partnership extends the qualified-supplier footprint, all resting on the commissioned 4500/5100T forging system.

Happy Forgings: record margins, and two trend lines going the wrong way

Q1 performance. Revenue rose 27.0% to ₹449 Cr (announced 4 August 2026), with finished-goods volume up 23.1% to 17,793 MT and realisation up 3.2% to ₹253 per kg. EBITDA was ₹141 Cr at a 31.3% margin, up 275 bps and the fourth consecutive quarter above 30%. PAT rose 39.2% to ₹91 Cr at a 20.4% margin, the first time above 20%, with EPS of ₹9.70 and zero exceptional items. Machining is now 90% of revenue. Price increases were negotiated after a three-year gap, with only about 30% of the benefit in Q1; the rest, including domestic hikes of roughly 4.5% to 5% from some OEMs, flows from Q2 onwards. Exports grew more than 30% to 28% of revenue.

Quality and sustainability. High. The margin is driven by price revisions, product mix (fully machined components carry 80% to 85% gross margins per the order book) and operating leverage. Management guides to high-teen volume growth for FY27 with EBITDA margin "broadly in line with FY26" (about 30.4%) and potential upside, and a captive solar project could add 1% to 1.5% of margin from FY28. The order book of about ₹950 Cr is roughly 60% export-oriented (Industrial 40%, Passenger Vehicles 25% to 30%). The risks: Commercial Vehicles (33%) plus Farm Equipment (32%) is still about 65% of revenue, farm-equipment exports to the US and Europe remain subdued, and FY26 cost inflation of about 2% to 2.5% of revenue was only 70% to 80% passed through.

Why it failed the screen. Debt/equity rose from 0.123 to 0.155 and ROCE slipped from 17.7% to 16.8%. The absolute levels are comfortable (D/E 0.155, net debt/EBITDA 0.56x, interest coverage 39.8x, FY26 ROE 15.2%), but both trend lines ran the wrong way over the window, and capex ran at 27.7% of revenue with FCF margin at minus 0.6% as a 4,000-ton forging press and 7,200 MT of machining lines were added in Q1. The screen is direction-based, and the direction was wrong.

Three growth drivers.
1. Export-led order-book conversion: about 60% of the ₹950 Cr book is export, Europe is roughly 60% of exports, and a dedicated North America team is responding to CV OEM RFQs with ramp-up expected from Q2 FY27.
2. Utilisation ramp on new capacity: forging at 59% and machining at 78% on a 1,52,000 MT forging and 75,200 MT machining base.
3. Mix shift into passenger vehicles and industrial plus the solar kicker: export PV revenue more than doubled in Q1, and solar adds 1% to 1.5% of EBITDA margin from FY28.

Ramkrishna Forgings: a capex-trough ROCE with a guided recovery

Q1 performance. Revenue rose 19.8% to ₹1,216.67 Cr year on year, though it was essentially flat sequentially. EBITDA was ₹218 Cr at a 17.96% margin, up 332 bps year on year and 85 bps quarter on quarter, with gross margin at 54.07%, which management called sustainable. PAT rose 297.6% to ₹46.88 Cr off a weak base (EPS ₹2.58 versus ₹0.65), and PBT more than doubled from ₹24 Cr to ₹65 Cr. PAT fell 16.2% quarter on quarter because depreciation and finance costs rose and the rail-wheel JV booked a ₹0.61 Cr share of loss.

Quality and sustainability. The margin gain is structural: better product mix, operating leverage and stabilised energy and shipping costs, with no currency benefit since export contracts carry currency pass-through. Two qualifiers: revenue is flat sequentially, and the PAT jump is a low-base recovery, since Q1 FY26 PAT was only ₹11.79 Cr. Standalone exports were ₹353.87 Cr, 32.5% of standalone revenue, with management targeting 35% of consolidated revenue and more than 20% growth expected from North America and Europe.

Why it failed the screen. ROCE collapsed from 40.9% to 6.4% and debt/equity rose from 0.663 to 0.710. The collapse is a capex-cycle trough, not an operating collapse: ₹3,676 Cr was invested over FY23 to FY26 (₹3,131 Cr in forging, casting and machining, ₹300 Cr in acquisitions, ₹245 Cr in the rail-wheel JV), capital employed rose 19.14% to ₹4,832.60 Cr, and FY26 PBT fell 47.8% to ₹116.71 Cr, including ₹51.17 Cr of one-off provisions (₹41.76 Cr electricity-duty provision, ₹9.41 Cr labour-code costs). Net debt/EBITDA went from 2.0x in FY24 to 4.64x in FY26 and interest coverage from 5.3x to 3.1x. The new assets were capitalised before they earned: the rail JV (51% with Titagarh, a ₹2,000 Cr project) began commercial operations only around end-June 2026, and the 28,800 MT casting line achieved commercial production on 31 March 2026, so both contributed zero revenue in FY26 while depreciation hit immediately. The turn has begun: net debt was cut ₹100 Cr in Q1 to ₹1,900 Cr, about ₹400 to 500 Cr of further reduction is targeted in FY27, and capex is capped at roughly ₹350 Cr versus ₹923.7 Cr in FY26. Management guides ROCE to 12% to 15% in FY27 and about 20% in FY28 as utilisation reaches 80% or more and the JV ramps up, with bulk production expected around September to October 2026 and 1,10,000 wheels of confirmed offtake. The market's 32.7% one-month move is pricing that guided recovery, not the reported ROCE.

Three growth drivers.
1. Rail-wheel JV ramp: 2,28,000 wheels per annum capacity, Asia's second-largest facility, with 1,10,000 wheels of confirmed offtake (80,000 from Indian Railways) sustaining production through end-FY28.
2. Operating leverage on the expanded base: 80% to 85% total utilisation targeted by end-FY27, with export realisations the primary margin lever.
3. Exports and non-auto mix: exports to exceed 40% of volume within two years, a ₹250 Cr North America energy-storage order, the Mexico plant, and EV targeted at 10% of revenue within two years.

All six, side by side

The comparison table keeps the screen's own arithmetic: revenue and PAT growth for the quarter, the headline margin change, and the two balance-sheet lines that did the separating.

All six cleared the price gate; the momentum picture differs sharply within it. INVPRECQ and HAPPYFORGE sit at their 52-week highs, KENNAMET is furthest below at 4.7%.

And the aggregate view makes the misread explicit. On average, the near-misses grew faster on paper than the qualifiers, and they still failed the screen, because the balance sheet did not confirm the income statement.

The ranking of the qualifiers

A descriptive ranking of the three companies that cleared every gate, on the screen's own evidence:

The takeaway: the income statement tells you about the quarter, the balance sheet about the trend

The screen is strict by design, and the strictness is the point. A company can post a spectacular quarter and still be getting structurally worse, the way PTCIL is when capex runs at 45.5% of revenue and operating cash flow is negative. A company can post modest headline growth and still be compounding, the way Shaily is while its mix shifts toward drug-delivery devices and its debt ratio falls. The qualifier list is not a list of the fastest growers. It is a list of companies whose quarters and balance sheets agree.

What to watch

• Kennametal India: whether the tungsten environment normalises and Machining Solutions turns around. The 24.8% PBT margin exit rate is a high bar for the next quarter.
• Shaily: consumer demand and the pen ramp to about 75 million units, and whether the 36 million-unit FY27 pen guidance is beaten after last year's miss.
• Investment & Precision Castings: disclosure of defence order values and continued volume momentum. With 50% capacity headroom, growth should not need debt.
• PTC Industries: cash from operations versus capex in every quarter, since growth is currently funded by debt.
• Happy Forgings: whether ROCE stabilises as the new press and machining lines fill and the price-increase benefit flows from Q2.
• Ramkrishna Forgings: the rail-JV bulk production start, expected around September to October 2026 per management, and the pace of the ₹400 to 500 Cr debt reduction. Reported ROCE should start climbing toward the guided 12% to 15%.

Frequently asked questions

Why were companies with faster growth excluded?
The screen requires all seven criteria at once, and the balance-sheet gate is not optional. PTCIL, HAPPYFORGE and RKFORGE each passed the Q1 income tests and the price tests but failed on debt/equity direction or ROCE direction, so they were excluded regardless of how strong the quarter looked.

What drove Kennametal's margin jump?
Operating leverage in the Hard Metal segment. Revenue grew 47.7% while total expenses grew only 26.2%, and the segment that contributes 93.7% of revenue swung its segment margin from 16.2% to 31.0%. Management attributes it to broad-based demand and volume growth, against a volatile tungsten cost backdrop.

Why is Shaily's healthcare mix the key story?
Healthcare crossed 50% of revenue for the first time in Q1, growing 84.4%, and it is structurally higher-margin than the consumer home-furnishings business. It is also the source of the forward visibility: pen-injector capacity rises to about 75 million units per annum and management is confident of beating the 36 million-unit FY27 guidance.

Is Ramkrishna Forgings' ROCE collapse permanent?
The evidence says no. The 40.9% to 6.4% fall reflects a ₹3,676 Cr capex cycle whose assets were capitalised before they earned revenue, plus ₹51.17 Cr of one-off FY26 provisions. Management guides ROCE to 12% to 15% in FY27 and about 20% in FY28, and Q1 already cut net debt by ₹100 Cr. The market's one-month move is pricing that guided recovery.

Why was PTC Industries excluded despite PAT growth of 466%?
Because the balance sheet ran the wrong way. Debt/equity rose from 0.044 to 0.173, CFO/EBITDA is minus 33.1%, capex is 45.5% of revenue and FCF margin is minus 55.3%, meaning the growth is being funded with debt. ROCE improved but from a low base, and the screen requires deleveraging, not the opposite.

How were margins compared across companies?
Each company reports a different headline margin, so the margin-change chart uses the basis each company itself highlights: PBT margin for Kennametal, net margin for Investment & Precision Castings, EBITDA margin for the others. The direction is comparable; the level is not.

Data note

All figures are from structured Q1 FY27 filings, investor presentations, concall transcripts, annual reports, the point-in-time ratio panel and daily price series, as of 19 August 2026. Consolidated numbers are used where available. Kennametal India's fiscal year ends 30 June, so its April to June 2026 quarter is the comparable period to other companies' Q1 FY27. PTCIL revenue growth is shown as +83.0% on total income; the results feed's +97.4% uses revenue from operations. INVPRECQ's +21.2% is the company-reported figure; the structured filing implies +18.9% on a slightly different year-ago revenue base. Shaily PAT growth is +16.8% per the structured filing, versus +17.1% in the company's announcement. Margin-change figures use each company's headline margin basis. The qualifier-versus-near-miss averages are unweighted means of three companies each. Sixteen of the 52 universe names had no extracted Q1 data and were not screened. The live metrics snapshot for RKFORGE carries data-quality flags, so its trajectory is built on the point-in-time panel and filings. ROCE panel values for KENNAMET use the earliest available point (November 2025) because the year-ago point is not available.

This is historical/descriptive analysis, not investment advice. It is educational analysis, not prepared by a SEBI-registered Research Analyst.